MEDBOT-B's stock plummeted 5.38% during intraday trading on Wednesday, as the medical robotics company faced significant selling pressure.

The decline was primarily triggered by substantial institutional selling, with multiple entities under Hillhouse Capital reportedly reducing their holdings significantly. Market concerns also persisted over the possibility that parent company MicroPort Medical may sell robotics business equity to alleviate cash flow pressures, creating further valuation overhang for MEDBOT-B.

At the sector level, the broader Health Care Equipment industry showed weakness, amplifying downward pressure on individual stocks. The company remains in a loss-making stage with negative financial metrics, contributing to elevated risk-averse sentiment among investors in the current market environment.